Using the physician global assessment in a clinical setting to measure and track patient outcomes

JAMA Dermatology

Volumn 151, Issue 4, 2015, Pages 375-381

  Pascoe, Vanessa L ^a,b   Enamandram, Monica ^c   Corey, Kristen C ^d   Cheng, Carol E ^a,e   Javorsky, Emilia J ^d   Sung, Sarah M ^b   Donahue, Kevin R ^a   Kimball, Alexandra B ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACNE; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT GLOBAL ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; RELIABILITY; SCORING SYSTEM; ACNE VULGARIS; DERMATOLOGY; MIDDLE AGED; PATHOLOGY; PHYSICIAN; PROCEDURES; REPRODUCIBILITY; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ACNE VULGARIS; ADULT; DERMATOLOGY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PHYSICIANS; PSORIASIS; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928253726     PISSN: 21686068     EISSN: 21686084     Source Type: Journal    
DOI: 10.1001/jamadermatol.2014.3513     Document Type: Article

References (21)

1. Elston DM, Sieck CK, Sullivan JN, Behal R, Kaleba EO. Developing ambulatory care physician performance measures. J Am Acad Dermatol. 2008;59(3):505-513.
2. Fitzgerald AA, Allen LA, Masoudi FA. The evolving landscape of quality measurement for heart failure. Ann N Y Acad Sci. 2012;1254:131-139.
3. Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11:79-99.
4. Grekin SJ, Ellis CN. Evaluating the severity of dermatologic disorders. Dermatol Ther. 2009;22(3):191-198.
5. Wilson RL, Feldman SR. Physician performance measures in dermatology. J AmAcad Dermatol. 2010;63(2):e29-e35.
6. Freedman JD, Gottlieb AB, Lizzul PF. Physician performance measurement: tiered networks and dermatology (an opportunity and a challenge). J Am Acad Dermatol. 2011;64(6):1164-1169.
7. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? a systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. J AmAcad Dermatol. 2012;66(3):369-375.
8. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Guidance for industry: acne vulgaris: developing drugs for treatment. http://www.fda.gov/downloads/Drugs/⋯/Guidances/UCM071292.pdf. Accessed October 3, 2014.
9. Tan JK, Fung K, Bulger L. Reliability of dermatologists in acne lesion counts and global assessments. J Cutan Med Surg. 2006;10(4):160-165.
10. Eichenfield LF, Hebert AA, Schachner L, Paller AS, Rossi AB, Lucky AW. Tretinoinmicrosphere gel 0.04%pump for treating acne vulgaris in preadolescents: a randomized, controlled study. Pediatr Dermatol. 2012;29(5):598-604.
11. Feldman SR, Fried RG, Herndon JH Jr, et al. Digital videography assessment of patients' experiences using adapalene-benzoyl peroxide gel in the treatment of acne vulgaris. J Drugs Dermatol. 2012;11(8):919-925.
12. Green L, Kircik LH, Gwazdauskas J. Randomized, controlled, evaluator-blinded studies conducted to compare the efficacy and tolerability of 3 over-the-counter acne regimens in subjects with mild or moderate acne. J Drugs Dermatol. 2013;12(2):180-185.
13. Palli MB, Reyes-Habito CM, Lima XT, Kimball AB. A single-center, randomized double-blind, parallel-group study to examine the safety and efficacy of 3mg drospirenone/0.02mg ethinyl estradiol compared with placebo in the treatment of moderate truncal acne vulgaris. J Drugs Dermatol. 2013;12(6):633-637.
14. Tan JK, Jones E, Allen E, Pripotnev S, Raza A, Wolfe B. Evaluation of essential clinical components and features of current acne global grading scales. J AmAcad Dermatol. 2013;69(5):754-761.
15. Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J AmAcad Dermatol. 2004;51(4):563-569.
16. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T. How good are clinical severity and outcome measures for psoriasis? quantitative evaluation in a systematic review. J Invest Dermatol. 2010;130(4):933-943.
17. Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res. 2013;22(9):2489-2499.
18. Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol. 2009;129(9):2136-2141.
19. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996;135(4):533-537.
20. Sampogna F, Picardi A, Melchi CF, Pasquini P, Abeni D. The impact of skin diseases on patients: comparing dermatologists' opinions with research data collected on their patients. Br J Dermatol. 2003;148(5):989-995.
21. Armstrong AW, Parsi K, Schupp CW, Mease PJ, Duffin KC. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol. 2013;149(5):577-582.